AnaptysBio, Inc.
ANAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $76,320 | $22,263 | $27,771 | $43,113 |
| % Growth | 242.8% | -19.8% | -35.6% | – |
| Cost of Goods Sold | $31,407 | $37,824 | $41,180 | $42,589 |
| Gross Profit | $44,913 | -$15,561 | -$13,409 | $524 |
| % Margin | 58.8% | -69.9% | -48.3% | 1.2% |
| R&D Expenses | $31,407 | $37,824 | $41,180 | $42,589 |
| G&A Expenses | $10,209 | $10,609 | $14,130 | $10,194 |
| SG&A Expenses | $10,209 | $10,609 | $14,130 | $10,194 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$31,407 | -$37,824 | -$41,180 | -$42,589 |
| Operating Expenses | $10,209 | $10,609 | $14,130 | $10,194 |
| Operating Income | $34,704 | -$26,170 | -$27,539 | -$9,670 |
| % Margin | 45.5% | -117.5% | -99.2% | -22.4% |
| Other Income/Exp. Net | -$19,591 | -$12,421 | -$11,746 | -$12,120 |
| Pre-Tax Income | $15,113 | -$38,591 | -$39,285 | -$21,790 |
| Tax Expense | $0 | $39 | $44 | -$6 |
| Net Income | $15,113 | -$38,630 | -$39,329 | -$21,784 |
| % Margin | 19.8% | -173.5% | -141.6% | -50.5% |
| EPS | 0.54 | -1.34 | -1.28 | -0.77 |
| % Growth | 140.3% | -4.7% | -66.2% | – |
| EPS Diluted | 0.52 | -1.34 | -1.28 | -0.77 |
| Weighted Avg Shares Out | 29,063 | 28,810 | 30,644 | 30,448 |
| Weighted Avg Shares Out Dil | 29,018 | 28,810 | 30,644 | 30,448 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,924 | $3,654 | $4,413 | $5,263 |
| Interest Expense | $22,515 | $19,606 | $18,061 | $17,404 |
| Depreciation & Amortization | $610 | $601 | $606 | $601 |
| EBITDA | $38,238 | -$18,384 | -$20,618 | -$3,806 |
| % Margin | 50.1% | -82.6% | -74.2% | -8.8% |